Screener
Eton Pharmaceuticals, Inc. ETON Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-017064
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Cash flows used in investing activities | ||
| Purchases of product license rights | (15,000) | — |
| Purchases of property and equipment | (75) | — |
| Net cash used in investing activities | (15,075) | — |
| Cash flows from financing activities | ||
| Proceeds from stock option exercises | 1,389 | 394 |
| Net cash from financing activities | 1,389 | 394 |
| Change in cash and cash equivalents | (6,281) | 2,484 |
Document
FAQ
- What is Eton Pharmaceuticals, Inc.'s investing cash flow?
- Eton Pharmaceuticals, Inc. (ETON) reported investing cash flow of -$15.08M in Q1 2026.
- What is the long-term trend for Eton Pharmaceuticals, Inc.'s investing cash flow?
- Over 2 years (2022 to 2025), Eton Pharmaceuticals, Inc.'s investing cash flow has grown at a -65.4% compound annual growth rate (CAGR), from -$2.79M to -$333K.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Eton Pharmaceuticals, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude